Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Middleton

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of the National Cancer Institute|October 9, 2008
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trialTim Eisen, Stéphane Oudard, Cezary Szczylik, et al.
Environmental Science & Technology|July 1, 2016
CO2 Accounting and Risk Analysis for CO2 Sequestration at Enhanced Oil Recovery SitesZhenxue Dai, Hari Viswanathan, Richard Middleton, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxinGuy R Seabrook, Kathy G Sutton, Wolfgang Jarolimek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.
Gynecologic Oncology|July 4, 2012
Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking PartnershipCamille Maringe, Sarah Walters, John Butler, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of the National Cancer Institute|October 9, 2008
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trialTim Eisen, Stéphane Oudard, Cezary Szczylik, et al.
Environmental Science & Technology|July 1, 2016
CO2 Accounting and Risk Analysis for CO2 Sequestration at Enhanced Oil Recovery SitesZhenxue Dai, Hari Viswanathan, Richard Middleton, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxinGuy R Seabrook, Kathy G Sutton, Wolfgang Jarolimek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.
Gynecologic Oncology|July 4, 2012
Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking PartnershipCamille Maringe, Sarah Walters, John Butler, et al.
Pageof 2